Subarachnoid pharmacotherapy for maximizing recovery after cortical ischemic stroke

Nandor Ludvig, M.D., Ph.D.

NYU Comprehensive Epilepsy Center, NYU, School of Medicine/Langone Medical Center, New York, NY USA

Abstract

Subarachnoid pharmacotherapy, a novel therapeutic strategy for the treatment of focal neocortical epilepsy, could be adapted for the treatment of stroke. Specifically, subarachnoid pharmacotherapy could be adapted to maximize functional recovery after cortical ischemic stroke. The key element of this strategy is a device implanted chronically in the subarachnoid space overlaying the cortical infarct and penumbra. The triple functions of this device are: (a) periodic transmeningeal drug delivery to promote neuroregeneration in the penumbra without causing damage by penetration into the cortical tissue, (b) periodic removal of accumulated inflammatory cells and molecules from the drug delivery site to prevent clogging in the drug delivery system, and (c) periodic detection of local EEG signals to monitor the efficacy of the subarachnoid drug treatment and to help to optimize drug delivery/fluid removal parameters. All functions of the device are regulated by a connected control implant. Preliminary safety studies in bonnet macaques not subjected to experimental stroke showed that the subarachnoid device is well tolerated and can perform its triple functions for months without causing apparent neurological or behavioral abnormality. Relevant efficacy tests in animal models of cortical ischemic stroke are needed to predict the clinical potential of subarachnoid pharmacotherapy for post-stroke recovery.

Keywords: Cortical stroke; Subarachnoid space; Intracranial drug delivery; Cerebrospinal fluid.

1. Introduction

Stroke is the leading cause of adult disability in the US. According to the American Stroke Association, about 795,000 Americans each year suffer a new or recurrent stroke (http://strokeassociation.org). The costs of long-term care and management of this patient population are about $65.5 billion per year (Rosamond et al., 2008). The magnitude of this health care problem is growing, due to (a) the aging of the population, (b) the limited success of current rehabilitation methods, and (c) the fact that "treatments for acute stroke such as lytics, neuroprotection, and clot-retrieving devices have had minimal impact" on post-stroke recovery (Domboy, 2009). To solve this problem, new therapeutic approaches are needed. This article presents a brief introduction to the concept, supporting data and prospects of subarachnoid pharmacotherapy specifically for maximizing recovery after cortical ischemic stroke.

2. The concept of subarachnoid pharmacotherapy for post-stroke recovery

Subarachnoid pharmacotherapy is a novel concept for the treatment of neurological disorders with localized cerebral cortical pathology. Extensive studies have been devoted to explore the potential of this strategy for the treatment of focal neocortical epilepsy (Ludvig et al., 2006, 2009, 2010a,b; Madhavan et al., 2008), but similar studies have yet to be conducted in the field of stroke research. The concept of subarachnoid pharmacotherapy for maximizing recovery after cortical ischemic stroke (Fig. 1) is based on four considerations.
First, a large number of stroke patients suffer specifically from cortical stroke, where the lesion is localized to cerebral cortical areas (Cramer and Crafton, 2006). A study by Halkes et al. (2006) determined that as much as 29% of patients with a single ischemic lesion had their lesion localized to the cerebral cortex. Thus, cortical ischemic stroke is a localized brain disorder, and therefore the optimal way to reverse its debilitating symptoms, once they occurred, is to access the site of the cortical infarct and its surrounding region, the penumbra, and apply a therapeutic procedure locally that restores function in the reversibly damaged cell population.

Second, the physicochemical properties of the cortical pia mater, a single interrupted layer of elongated cells (Lopes and Mair, 1974), allow the diffusion of water-soluble drugs through its layer into the underlying cortical tissue, permitting these molecules to exert neuropharmacological effects in animals, including nonhuman primates (Ludvig et al., 2008, 2009). In fact, the similar permeability of the spinal pia mater (Bernards and Hill, 1990) is exploited in medical practice for intrathecal anesthesia and pain relief: a practice that could certainly be adapted to the localized pharmacological treatment of brain disorders, including stroke.

Third, the approximately 3 mm gap between the cranial arachnoid and pia mater is filled with cerebrospinal fluid (CSF), offering the opportunity to implant a drug-delivery unit in this meningeal compartment, over the area of cortical stroke. This...
would create a direct access to the site of the cortical infarct and penumbra, as well as a means to treat this site with locally delivered drugs.

Fourth, the basic hardware and software for a subarachnoid pharmacotherapy device, albeit for the purpose of preventing focal neocortical seizures, has already been developed and successfully tested in monkeys (Ludvig et al., 2010b). Fig. 2 shows one of these monkeys, implanted with a subarachnoid drug-delivery unit, which itself is connected to a dual mini-pump regulated by a battery-powered microcontroller and a radiofrequency (RF) module (designers: Geza Medveczky and Sandor Toth; manufacturer: Cygnus, Paterson, NJ) for wireless communication. Although in the present studies these control units are secured to the cranium for easy access and replacement, if necessary, and thus their full implantation in the body has yet to be achieved, the essentials of the technology is available for adaptation to the treatment of post-stroke recovery.
The subarachnoid unit, which would allow the implementation of the concept of localized pharmacotherapy for cortical stroke, is a less than 2 mm thick silicone sheet, shaped as a grid or strip incorporating multiple units of sealed fluid-exchanging ports and recoding electrodes (Fig. 1). This unit, designed by Richard Rizzolo and the author, is manufactured at DocXS Biomedical Products, Ukiah, CA. Although not yet approved by FDA, it is available for animal experiments. Each fluid-exchanging port has two openings. One of these openings serves to deliver a therapeutic drug solution into the lumen of the port and, via this route, into the infarct and the peri-infarct area (penumbra). This drug solution can contain (a) excitatory neurotransmitters or neurotransmitter agonists without excitotoxic action, such as low micromolar concentrations of acetylcholine, (b) drugs that facilitate antiapoptotic cellular mechanisms via the erythropoietin receptors (Sairanen et al., 2006) and other mechanisms, (c) neurotrophins promoting axonal regeneration (Selzer, 2005), (d) antibodies against axonal growth-inhibitory molecules (Selzer, 2005; Carmichael, 2006), (e) protease inhibitors (Rami and Krieglstein, 1993), (f) antioxidants, (g) agents promoting ischemia-induced cortical neurogenesis (Ohira et al., 2010): a class of drugs that has yet to be identified, and (h) other compounds. The other opening of the fluid-exchanging port serves to remove local CSF and, via this mechanism, to eliminate locally accumulating inflammatory cells (e.g., proliferating fibroblasts, lymphocytes, etc.) and molecules (e.g., collagen, adhesive glycoproteins, etc.) that invade all intracranial implants (Del Bigio, 1998). Elimination of these cells and molecules appears to be necessary to prevent clogging in the drug delivery system and achieve effective drug delivery through the pia mater into the underlying cortex (Ludvig et al., 2010b). One function of the dual minipump, besides delivering a drug solution, is to collect the removed local CSF and its sterile inflammatory products into a reservoir. This reservoir is connected to a subcutaneous port, through which the collected CSF can be permanently removed from the body. (A similar, adjacent subcutaneous port serves for the periodic refilling of the dual minipump’s drug-reservoir).

The subarachnoid grid or strip also incorporates EEG recording contacts (supplied to the above DocXS device by Ad-Tech Medical Instrument, Racine, WI) to allow the detection of local electrophysiological signals. This serves two purposes. First, external evaluation of the recordings could help to optimize the volume, duration and frequency of drug delivery so that ineffective and neurotoxic drug administration can be avoided. Second, the recordings could provide a sensitive means to monitor the recovery of the drug-exposed neural circuitry, helping to predict prognosis and adjust the treatment of the recovering patient. Indeed, it is known that during post-stroke recovery significant improvements occur in the EEG power spectrum, characterized primarily by decreasing delta and increasing theta power (Giaquinto et al., 1994). It has also been shown that the ischemic penumbra generates abnormal theta EEG waves (Fernandez-Bouzas et al., 2000). Giaquinto and his colleagues proposed as early as 1994 that quantitative EEG “can monitor mechanisms of local repair”. It is important to recognize that studies on EEG changes associated with post-stroke recovery have typically been performed with scalp electrodes, which are far less sensitive to capture fine EEG changes than intracortical electrodes. Thus, the intracranial electrodes of the subarachnoid pharmacotherapy device (Fig. 1) should yield enriched electrophysiological data that could effectively guide localized drug treatments for the cortical penumbra.

3. Supporting experimental data

The efficacy and safety of subarachnoid pharmacotherapy has not been investigated in animal models of cortical stroke. However, two sets of data support the clinical viability of this therapeutic approach. One dataset provides evidence for the diffusion of drugs from the subarachnoid space into the underlying cortical tissue with subsequent, localized pharmacological effects; the other dataset suggests that long-term subarachnoid drug delivery using the device shown in Fig. 1 is a safe procedure.

In rats, transmeningeal drug delivery into the neocortex can be performed by applying a drug solution epidurally, on the surface of the dura mater, as the thin...
the dura in this species allows drug diffusion through this meningeal layer into the subarachnoid space. Thus, epidurally administered diazepam, pentobarbital and muscimol have been shown to prevent and/or terminate experimentally induced focal neocortical seizures in rats (Collins, 1980; Eder et al., 1997; Stein et al., 2000; Ludvig et al., 2006, 2009). Relevant autoradiographic and histological studies have demonstrated the actual intracortical diffusion and spread of water-soluble drugs, such as acetylcholine, N-methyl-D-aspartate and methylene blue (Cornblath and Ferguson, 1976; Ludvig et al., 2008). Our study also revealed that this intracortical diffusion remain localized and its spatial spread can be controlled by the size of the sealed drug delivery device and by the adjustment of the hydrostatic pressure in its lumen. Unlike in rats, in monkeys, the subarachnoid strip or grid can be chronically implanted in the subarachnoid space. We showed that with such a device the epidural pharmacological data obtained in rats can be replicated in primates: subdural/subarachnoid muscimol completely prevented focal, acetylcholine (Ach)-induced neocortical seizures in monkeys in a concentration well tolerated by the animals (Ludvig et al., 2009). Fig. 3 illustrates these facts, demonstrating the localized neocortical diffusion of methylene blue after its delivery through the subdural space in a rat (A), and the localized pharmacological action of subdurally delivered, very high concentration of Ach in a monkey (B).

Relevance of these animal studies to humans was demonstrated by a study in a neurosurgical setting in patients with focal neocortical epilepsy (Madhavan et al., 2008). In this study, lidocaine was manually delivered onto the pial surface of the seizure focus prior to its resection. This treatment significantly reduced the frequency of epileptiform EEG spikes within minutes.

The success of subarachnoid pharmacotherapy for post-stroke recovery depends on the safety of this approach. We have shown in squirrel monkeys (Saimiri sciureus) that subdural/subarachnoid drug delivery/recording cups are well tolerated by the animals for several months (Ludvig et al., 2009). Recently, we implanted two adult bonnet macaques (Macaca radiata) with the type of subarachnoid device shown in Fig. 1 (Ludvig et al., 2010b). The key surgical implantation steps were: (a) performing a craniotomy close to the border of the treated cortical area, (b) making an incision in the exposed dura mater, (c) gently slipping the subarachnoid device under the dura and advancing it forward so the silicone...
sheet can fully cover the treated area, (d) securing the proximal edge of the device to the cranium, and (e) closing the craniotomy, with the electrode leads and fluid tubes externalized for subsequent connection to the control units of the apparatus. The device was tailored for use in nonhuman primates, thus shaped as a strip with two fluid-exchange ports equipped with EEG electrode contacts. The fluid-exchange ports served for delivering saline or drugs at 12-h intervals in the first monkey. In the second monkey, the ports served for both delivering saline or drugs at 12-h intervals and removing local CSF at 6-h intervals, in an alternating fashion. (The dual mini-pump executing these fluid movements was designed by Geza Medveczky with inputs from the author. It is available from Cygnus (Paterson, NJ), presently for non-human use only.) Neurological signs or behavioral abnormality did not develop in the implanted monkeys. They vigorously moved around in the test chamber (Fig. 2, upper panel) and generated normal, physiological EEG signals in the implanted area (Fig. 2, lower panel) even 3 months after surgery. This also indicated that stable recordings can be obtained with the subarachnoid device for months. Furthermore, as shown in Fig. 4, the implanted monkeys performed a spatial memory task designed for nonhuman primates with an efficacy similar to that of non-implanted monkeys (Ludvig et al., 2003). Namely, the implanted bonnet macaques fully acquired the spatial memory task by the 10th (monkey 2) and 13th (monkey 1) sessions, as by that time their initial Reaches into Non-Baited Port values of 69 and 160, respectively, dropped to 0 (Fig. 4B). This is comparable to the performance of our previously examined, non-implanted squirrel monkeys in a similar 8-port task, where “...in the 1st session the monkeys reached into the non-baited ports on an average of 77 ± 13.37 (mean ± S.E.M.) occasions. This value dropped to as low as 8.66 ± 7.21 (mean ± S.E.M.) in the 15th session” (Ludvig et al., 2003). Since this task can only be performed with intact motor functions and motivational state, these results also seem to indicate that chronic, periodic subarachnoid fluid applications and removals do not cause apparent deterioration in neocortical physiological processes.

A

Fig. 4. Cognitive performance of monkeys implanted with the subarachnoid pharmacotherapy device. A: Photograph of a monkey performing the task in the test chamber. The chamber is equipped with 8 food ports (arrows) at various locations in the walls: the animal’s task is to remember the locations of the baited and non-baited ports and to avoid the non-baited ones. B: Reaches into the non-baited ports by two implanted monkeys during 15 test sessions in the indicated period. The decreasing number of reaches into the non-baited ports as the sessions unfolded indicates the acquisition of this spatial memory task by both monkeys.

The subarachnoid device became clogged in the first animal where only fluid delivery was performed, whereas its function remained intact in the second animal where fluid delivery was alternating with local CSF removal (Ludvig et al., 2010b). These preliminary data suggest that periodic drug delivery/fluid removal cycles can be maintained in the subarachnoid space. In summary, available experimental data suggest that subarachnoid fluid-exchanging/EEG recording devices can be implanted on the cerebral cortical surface in primates and that the multiple functions of these devices can be safely used for long periods.
4. The prospects of subarachnoid pharmacotherapy for stroke patients

Subarachnoid pharmacotherapy is not suitable for preventing stroke and is inadequate for treating subcortical cerebrovascular insults. Whether it can be considered for the treatment of hemorrhagic stroke has yet to be explored. However, it may have a niche in the rehabilitation of patients who suffered ischemic stroke localized to the cerebral cortical lobes. Specifically, subarachnoid pharmacotherapy may maximize post-stroke recovery in these patients by the virtue of facilitating/promoting plastic neuronal regeneration in the peri-infarct area: the region that holds the key to functional recovery in this disease. The general idea of treating stroke at the site of the cerebrovascular insult is not new. Several research groups have started to investigate the therapeutic potential of localized, intracranial drug delivery in stroke. Thus, Saleh et al. (2001) explored the beneficial effect of local microinjection of estrogen into the insular cortex before inducing experimental stroke in rats by middle cerebral artery occlusion. Using the same stroke model, Ding et al. (2004) achieved as much as 90% infarct reduction by the administration of cold saline into the ischemic territory, while Pignataro et al. (2007) showed that the intracerebral delivery of acid-sensing ion channel (ASIC) blockers can reduce the volume of such infarcts by >50%. Therefore, to this author it seems justified to extend these studies to the investigation of the therapeutic potential of temporally and spatially controlled drug delivery/flow removal cycles with subdurally implanted devices in animal models of cerebral cortical ischemic stroke.

The challenge of relevant animal studies remains enormous. Do neurotrophins, antibodies, and other potentially therapeutic proteins diffuse from the subarachnoid space transmeningeally into the cortical tissue, just as water-soluble small molecules do? If yes, do these molecules retain their therapeutic efficacy in vivo, in real-life conditions? Does the peri-infarct cortical penumbra also react to overlaying subarachnoid devices in the same way as the physiologically perfused cortical tissue? If not, is the chronic use of such subarachnoid implants safe in stroke patients? What are the optimal subarachnoid drug combinations for maximizing post-stroke recovery and what are the optimal time-windows for applying these drug combinations? Does the efficacy of controlled subarachnoid drug administration to restore cortical neural functions after stroke exceed the efficacy of oral/parenteral pharmacotherapies? Can the subarachnoid device be safely removed 6 – 12 months after implantation, once its therapeutic use is completed? Is, in fact, such a removal necessary, even if the device induces no local pathology? Nevertheless, as “stroke recovery represents an important and underexplored opportunity for the development of new stroke treatments” (Cairns and Finklestein, 2003), seeking answers to those questions via animal studies should contribute to the development of effective therapy for post-stroke disability.

The animal experiments themselves may ideally involve studies in both rats and monkeys. The photothermometric model of ischemic cerebral cortical stroke (Watson et al., 1985; Kelly et al., 2001), seems to be well-suited to elaborate much of the pharmacology of maximized post-stroke recovery, though the technical details of drug delivery into the penumbra through multiple epidural cups equipped with EEG electrodes need to be worked out. At the same time, monkey studies could be used for testing various subarachnoid strips and grids, as well as various engineering solutions for the control devices, tailored specifically for post-stroke therapy. For these purposes the similar anatomy of monkeys and humans offer better testing conditions than rats.

The scientific and engineering challenges of subarachnoid pharmacotherapy for stroke cannot overshadow the significance of relevant ethical problems, as these latter should be faced, examined and solved before proceeding to applications for regulatory approvals and subsequent clinical trials. One ethical problem is the necessity of animal studies in the preclinical device-development phase, as neither computer models nor in vitro preparations can mimic the complex chain of events following cortical ischemic stroke. Yet, living creatures are subjected to stroke to gain knowledge on these events. To explain the continued necessity of animal experiments for the development of intracranial therapeutic devices, this author recently argued that “...there is an unceasing force in history that compels mankind to decode the laws of the universe, including those that produced the brain, partly to make improvements on this organ and eliminate its diseases, with implanted devices if necessary, and if this is true, then animal experimentation, since it is absolutely necessary for understanding the complex interactions between the brain and an intracranially implanted therapeutic device, must be in harmony with the very historic force that presses mankind to acquire knowledge”. (Ludvig, 2008). While that historic force often and inevitably disturbs balance between humans and animals, developers of the proposed subarachnoid stroke therapy could contribute, however modestly, to the restoration of that balance by voluntarily supporting wildlife conservation/animal welfare causes. The other main ethical problem is the possibility of abuse, as unlike neurostimulators, intraventricular shunts, stents, and other neurosurgical implants, subarach-
Subarachnoid pharmacotherapy devices have the potential for the first time to affect higher mental functions, by the mere virtue of delivering drugs into the cerebral cortex, including the association cortex. Thus, should future animal studies prove that the strategy described in this paper is indeed a promising one, warranting clinical trials, effective safeguards must be developed to exclude any possibility of using this medical technology for purposes other than to help stroke patients to recover and regain their physical and mental strength.

Acknowledgment
This work was supported by a NYU – Polytechnic Institute of NYU Seed Grant, Grant #140929 from the Epilepsy Research Foundation, and funds from Finding Cure for Epilepsy & Seizures (FACES), to N.L. The experiments illustrated in Figs. 2 – 4 were carried out by the technical assistance of Hai M. Tang, M.D., and Shirn L. Baptiste, B.S. Veterinary advice for the nonhuman primate studies has been provided by Carol Novotney, D.V.M. I am grateful to John G. Kral, M.D., Ph.D. for his encouragement and suggestions throughout my decade-long work on the development of intracranial therapeutic devices. My colleagues at NYU Comprehensive Epilepsy Center, Orrin Devinsky, M.D., Ruben I. Kuzniecky, M.D., Werner K. Doyle, MD, Jacqueline A. French M.D. and Chad Carlson, M.D., have provided an inspiring environment for developing new therapies for epilepsy. I thank Maudy L. Benz, M.F.A., for her editorial assistance to this paper.

Conflict of Interest
None

References


